Remote home rehabilitation improves quality of life in pulmonary hypertension patients

Mobile Internet-based Remote Home Rehabilitation Improves Prognostic Function and Quality of Life in Pulmonary Hypertension: a Prospective Single-center Randomized Controlled Study

This study tests if a remote home rehabilitation program can help people with pulmonary hypertension feel better and improve their quality of life compared to those who just follow their usual routine after leaving the hospital.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 80 (estimated)
• Ages: 18 Years to 60 Years
• Sex: All
• Sponsor: China-Japan Friendship Hospital (Academic / other)
• Locations: 1 site (Beijing, Beijing Municipality)
• Trial ID: NCT06362382 on ClinicalTrials.gov

What this trial studies

This clinical trial investigates the effectiveness of mobile Internet-based remote home rehabilitation for patients with pulmonary hypertension. Participants will engage in tele-rehabilitation training, which includes impedance training, under the guidance of a rehabilitation trainer and psychotherapist during their hospital stay. The study compares the outcomes of the tele-rehabilitation group with a control group receiving health education and following their usual routine post-discharge. The primary focus is to assess improvements in prognostic function and quality of life.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-60 with diagnosed pulmonary hypertension who can use smartphones and monitoring devices.

Not a fit: Patients with acute pulmonary embolism or serious arrhythmias may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could significantly enhance the quality of life and health outcomes for patients with pulmonary hypertension.

How similar studies have performed: While tele-rehabilitation is a growing field, this specific approach for pulmonary hypertension is relatively novel and has not been extensively tested.

Eligibility criteria

Inclusion Criteria:

* 1\. age 18- 60 years old;
* 2\. PH were defined as: mPAP \> 20 mmHg, PAWP ≦ 15 mmHg and PVR \> 2 WU measured by right heart catheterization at sea level at rest;
* 3\. Arterial Pulmonary Hypertension (PAH), pulmonary hypertension associated with lung diseaseor and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) according to the WHO PH Classification;
* 4\. no syncope or syncopal aura during walking or recovery.
* 5\. no serious arrhythmia caused by rest or exercise such as ventricular tachycardia, ventricular fibrillation, Class III atrioventricular block, etc.
* 6\. stable medication and medication regimen for at least 3 months prior to randomization and no organized exercise training of any kind for at least 3 months prior to screening
* 7\. be proficient in the use of smartphones and monitoring devices;
* 8\. sign an informed consent form.

Exclusion Criteria:

* 1\. combined with VTE.
* 2\. acute pulmonary embolism.
* 3\. low-intensity exercise (\<3METs) or angina pectoris symptoms/signs during the recovery period.
* 4\. hemodynamic abnormality during exercise (especially systolic blood pressure doesn't rise or fall or arrhythmia occurs when the exercise load is increased).
* 5\. severe psycho-cognitive disorders.
* 6\. couldent do exercise due to the neurological or musculoskeletal dysfunction.
* 7\. patients with CTEPH who are scheduled to undergo percutaneous pulmonary artery balloon dilatation or pulmonary artery endarterectomy within 6 months.
* 8\. patients with a combination of other consumptive underlying diseases, such as malignant tumors, pulmonary tuberculosis, hyperthyroidism, severe depression, etc.
* 9\. pregnancy.
* 10\. refused to sign the informed consent form.

Where this trial is running

Beijing, Beijing Municipality

• Fuwai Hospital — Beijing, Beijing Municipality, China (Recruiting)

Study contacts

• Study coordinator: Xiaoming Zhou, MD

Conditions Pulmonary Hypertension